EcoDrugPlus

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 1

Ensembl ID : ENSCCRG00000059174
Gene Symbol: HSP90AA1.1
1 Cross references
305 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSCCRG00000059456
Gene Symbol: HSP90AA1.2
1 Cross references
316 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSCCRG00000007442
Gene Symbol: HSP90AA1.2
1 Cross references
316 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSCCRG00000062663
Gene Symbol: HSP90AB1
1 Cross references
354 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSCCRG00000081064
Gene Symbol: HSP90AB1
1 Cross references
355 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSCCRG00000062103
Gene Symbol: HMGB1B
1 Cross references
507 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSCCRG00000007516
Gene Symbol: HMGB1B
1 Cross references
507 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSCCRG00000082749
Gene Symbol: HRH1
1 Cross references
186 Possible Orthologues:

Histone Deacetylase 1

Ensembl ID : ENSCCRG00000042730
Gene Symbol: HDAC1
1 Cross references
305 Possible Orthologues:

Histone Deacetylase 1

Ensembl ID : ENSCCRG00000009052
Gene Symbol: HDAC1
1 Cross references
305 Possible Orthologues:

Histone Deacetylase 10

Ensembl ID : ENSCCRG00000007678
Gene Symbol: HDAC10
1 Cross references
181 Possible Orthologues:

Histone Deacetylase 11

Ensembl ID : ENSCCRG00000046711
Gene Symbol: HDAC11
1 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).